TL-SBRT-nccRCCNCT07922928
Toripalimab and Lenvatinib With or Without SBRT Before Surgery for Non-Clear Cell Kidney Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Tumor Cell Necrosis Rate (TCNR)
Timeframe: At surgery following neoadjuvant treatment, approximately 5 to 6 months after the first dose.
Secondary (4)
R0 Resection Rate
Objective Response Rate (ORR)
Disease Control Rate (DCR)
Major Pathological Response (MPR) Rate
Arms and interventions
Toripalimab Plus LenvatinibActive comparator
Toripalimab 240 mg intravenously every 3 weeks plus lenvatinib 12 mg orally once daily for six 21-day cycles, followed by surgery.
Toripalimab Plus Lenvatinib and SBRTExperimental
Toripalimab 240 mg intravenously every 3 weeks plus lenvatinib 12 mg orally once daily for six 21-day cycles. SBRT at 40 Gy in five fractions is delivered to the primary renal tumor after cycle 2 and before cycle 4, followed by surgery.
Drugs: Toripalimab, Lenvatinib
Radiation: Stereotactic Body Radiotherapy